7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione

Catalog No. :
ACLRQE525
CAS No. :
52094-70-9
Molecular Formula :
C12H12N2O2
Molecular Weight :
216.24

IUPAC Name:3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione

7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$92.00Login to see priceInquiryInquiry
250mg95%$178.00Login to see priceInquiryInquiry
1g95%$340.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione
IUPAC Name3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione
MDL No.MFCD00001732
Molecular FormulaC12H12N2O2
Molecular Weight216.24
SMILESO=C1NC2(CC3=C(C=CC=C3)CC2)C(N1)=O
InChI KeyZWYUGDUPLSGYSK-UHFFFAOYSA-N
Synonym7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione;Tetrantoin;3',4'-Dihydrospiro[imidazolidine-4,2'(1'H)-naphthalene]-2,5-dione;S.2-676;Spiro[imidazolidine-4,2'-tetralin]-2,5-dione;Spiro[tetralin-2,4'-imidazolidine]-2',5'-dione;7,8-Benzo-1,3-diazaspiro(4.5)decane-2,4-dione;Benzo(G)quinazoline-2,4(1H,3H)-dione (8ci)
CAS No.52094-70-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACLRQE525 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLRQE525 route product structure diagram
    ACLRQE52552094-70-9
Inquiry

2. ACLRQE525 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLRQE525 route product structure diagram
    ACLRQE52552094-70-9
Inquiry

Comments (0)